RxDoctor Payments Data

Harbans Multani, MD

Psychiatry · Loma Linda, CANPI 1831175033

Payments from drug & device makers

$6,211in general payments, 2019–2025

Across 367 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$950
  • Alkermes, Inc.$911
  • Neurocrine Biosciences, Inc.$813
  • Teva Pharmaceuticals USA, Inc.$782
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$657
  • Sunovion Pharmaceuticals Inc.$495
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$6,209100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,211 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$175,891
Medicare patients
160
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$76,434
Abilify MaintenaAripiprazole26$67,522
Lurasidone Hcl29$29,780
Chlorpromazine Hcl113$26,052
TrintellixVortioxetine Hydrobromide44$21,095
CaplytaLumateperone Tosylate12$20,552
FanaptIloperidone12$18,807
LybalviOlanzapine/Samidorphan Malate11$16,041
Aripiprazole352$14,327
Quetiapine Fumarate700$9,813
Paliperidone ErPaliperidone13$6,432
Asenapine Maleate24$6,189
Haloperidol155$5,309
Risperidone457$5,306
Olanzapine425$5,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$466$76,43427 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$950$67,52226 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$36$21,09544 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$657$20,55212 claims
Vanda Pharmaceuticals Inc.Fanapt$230$18,80712 claims
Alkermes, Inc.Lybalvi$911$16,04111 claims
Almatica Pharma LLCSertraline Hcl$51$2,360359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →